Values are percentages (%). Reference
ligands (100%) were
P4Tooltip progesterone (medication) for the
PRTooltip progesterone receptor,
TTooltip testosterone (medication) for the
ARTooltip androgen receptor,
E2 for the
ERTooltip estrogen receptor,
DEXATooltip dexamethasone for the
GRTooltip glucocorticoid receptor,
aldosterone for the
MRTooltip mineralocorticoid receptor,
TTooltip testosterone (medication) for
SHBGTooltip sex hormone-binding globulin, and
cortisol for
CBGTooltip Corticosteroid-binding globulin.
^
abColton FB, Nysted LN, Riegel B, Raymond AL (1957). "17-Alkyl-19-nortestosterones". Journal of the American Chemical Society. 79 (5): 1123–1127.
doi:
10.1021/ja01562a028.
ISSN0002-7863.
^
abMiyake T, Pincus G (December 1958). "Progestational activity of certain 19-norsteroids and progesterone derivatives". Endocrinology. 63 (6): 816–824.
doi:
10.1210/endo-63-6-816.
PMID13609555.
^
abMcRobb L, Handelsman DJ, Kazlauskas R, Wilkinson S, McLeod MD, Heather AK (May 2008). "Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay". The Journal of Steroid Biochemistry and Molecular Biology. 110 (1–2): 39–47.
doi:
10.1016/j.jsbmb.2007.10.008.
PMID18395441.
S2CID5612000.
^Zeelen FJ (1990).
Medicinal chemistry of steroids. Elsevier Science Limited. pp. 108–109.
ISBN978-0-444-88727-6. Other examples are allylestrenol (42), a pro-drug converted to the 3-keto analogue (43), which is used in the treatment of threatened abortion [78,79] and altrenogest (44), used in sows and mares to suppress ovulation and estrus behaviour [80]. [...] Progestins with a 17a-allyl side chain: (42) allylestrenol, (43), (44) altrenogest.
^
abcdBergink EW, Loonen PB, Kloosterboer HJ (August 1985). "Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties". Journal of Steroid Biochemistry. 23 (2): 165–168.
doi:
10.1016/0022-4731(85)90232-8.
PMID3928974.
^Madjerek Z, De Visser J, Van Der Vies J, Overbeek GA (September 1960). "Allylestrenol, a pregnancy maintaining oral gestagen". Acta Endocrinologica. 35 (I): 8–19.
doi:
10.1530/acta.0.XXXV0008.
PMID13765069.